Published in J Pharm Sci on January 01, 2000
Balancing protection and release of DNA: tools to address a bottleneck of non-viral gene delivery. J R Soc Interface (2009) 1.22
Development of a serum-free co-culture of human intestinal epithelium cell-lines (Caco-2/HT29-5M21). BMC Cell Biol (2006) 1.10
TEER measurement techniques for in vitro barrier model systems. J Lab Autom (2015) 1.10
Delineation of human peptide transporter 1 (hPepT1)-mediated uptake and transport of substrates with varying transporter affinities utilizing stably transfected hPepT1/Madin-Darby canine kidney clones and Caco-2 cells. J Pharmacol Exp Ther (2005) 0.94
The effect of complexation hydrogels on insulin transport in intestinal epithelial cell models. Acta Biomater (2009) 0.92
Titanium dioxide nanoparticle impact and translocation through ex vivo, in vivo and in vitro gut epithelia. Part Fibre Toxicol (2014) 0.91
Glutamate reduces experimental intestinal hyperpermeability and facilitates glutamine support of gut integrity. World J Gastroenterol (2011) 0.89
Assessment of poly(methacrylic acid-co-N-vinyl pyrrolidone) as a carrier for the oral delivery of therapeutic proteins using Caco-2 and HT29-MTX cell lines. J Biomed Mater Res A (2010) 0.88
Modeling bioavailability to organs protected by biological barriers. In Silico Pharmacol (2013) 0.86
The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. Br J Clin Pharmacol (2003) 0.85
Proteomic profiling of halloysite clay nanotube exposure in intestinal cell co-culture. J Appl Toxicol (2013) 0.83
Pro-inflammatory cytokine regulation of P-glycoprotein in the developing blood-brain barrier. PLoS One (2012) 0.83
Cellular localization, invasion, and turnover are differently influenced by healthy and tumor-derived extracellular matrix. Tissue Eng Part A (2014) 0.82
Influence of fermentation conditions on the surface properties and adhesion of Lactobacillus rhamnosus GG. Microb Cell Fact (2012) 0.81
Robust bioengineered 3D functional human intestinal epithelium. Sci Rep (2015) 0.81
Protein expression profiles of intestinal epithelial co-cultures: effect of functionalised carbon nanotube exposure. Int J Biomed Nanosci Nanotechnol (2013) 0.80
Comparative study of nanoparticle-mediated transfection in different GI epithelium co-culture models. J Control Release (2012) 0.80
A Single Mutation in the Gene Responsible for the Mucoid Phenotype of Bifidobacterium animalis subsp. lactis Confers Surface and Functional Characteristics. Appl Environ Microbiol (2015) 0.79
Effect of a Semi-Purified Oligosaccharide-Enriched Fraction from Caprine Milk on Barrier Integrity and Mucin Production of Co-Culture Models of the Small and Large Intestinal Epithelium. Nutrients (2016) 0.78
Impact assessment of repeated exposure of organotypic 3D bronchial and nasal tissue culture models to whole cigarette smoke. J Vis Exp (2015) 0.78
Effects of silver nanoparticles and ions on a co-culture model for the gastrointestinal epithelium. Part Fibre Toxicol (2016) 0.78
Permeation of insulin, calcitonin and exenatide across Caco-2 monolayers: measurement using a rapid, 3-day system. PLoS One (2013) 0.78
pH-responsive hydrogels containing PMMA nanoparticles: an analysis of controlled release of a chemotherapeutic conjugate and transport properties. J Biomater Sci Polym Ed (2012) 0.77
An inulin and doxorubicin conjugate for improving cancer therapy. J Drug Deliv Sci Technol (2013) 0.77
Evaluation of nanosuspensions for absorption enhancement of poorly soluble drugs: in vitro transport studies across intestinal epithelial monolayers. AAPS J (2008) 0.76
Prediction of the permeability of neutral drugs inferred from their solvation properties. Bioinformatics (2015) 0.75
Hybrid responsive hydrogel carriers for oral delivery of low molecular weight therapeutic agents. J Drug Deliv Sci Technol (2015) 0.75
Subdiffusion in Membrane Permeation of Small Molecules. Sci Rep (2016) 0.75
Oral Toxicity and Intestinal Transport Mechanism of Colloidal Gold Nanoparticle-Treated Red Ginseng. Nanomaterials (Basel) (2016) 0.75
Design of pH-Responsive Biomaterials to Enable the Oral Route of Hematological Factor IX. Ann Biomed Eng (2016) 0.75
A technique to estimate in vivo dissolution profiles without data from a solution. AAPS J (2012) 0.75
Microscale Bioreactors for in situ characterization of GI epithelial cell physiology. Sci Rep (2017) 0.75
An integrated methodology for assessing the impact of food matrix and gastrointestinal effects on the biokinetics and cellular toxicity of ingested engineered nanomaterials. Part Fibre Toxicol (2017) 0.75
Microtechnology-Based Multi-Organ Models. Bioengineering (Basel) (2017) 0.75
Oleic Acid Uptake Reveals the Rescued Enterocyte Phenotype of Colon Cancer Caco-2 by HT29-MTX Cells in Co-Culture Mode. Int J Mol Sci (2017) 0.75
The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res (1997) 2.28
Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man. J Pharmacokinet Biopharm (1974) 2.18
Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm (2000) 2.14
Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res (1998) 2.08
Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res (1996) 2.05
A survey of the pharmacological properties of metoprolol in animals and man. Acta Pharmacol Toxicol (Copenh) (1975) 2.01
Clinical pharmacokinetics of metoprolol. Clin Pharmacokinet (1981) 1.94
Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol. Acta Pharmacol Toxicol (Copenh) (1975) 1.82
Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses. Biopharm Drug Dispos (1987) 1.70
5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res (1998) 1.66
Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin Pharmacol Ther (1997) 1.64
Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses. Acta Pharmacol Toxicol (Copenh) (1975) 1.57
Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp Ther (1992) 1.52
Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit (1990) 1.50
Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment. Clin Pharmacol Ther (1975) 1.44
Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci (2004) 1.41
Targeted prodrug design to optimize drug delivery. AAPS PharmSci (2000) 1.36
Felodipine kinetics in healthy men. Clin Pharmacol Ther (1985) 1.35
A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm (1999) 1.35
Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol (1995) 1.34
Pregnancy-induced increase in metoprolol metabolism. Clin Pharmacol Ther (1985) 1.30
Membrane topology of the human dipeptide transporter, hPEPT1, determined by epitope insertions. Biochemistry (1998) 1.23
Human postprandial gastric emptying of 1-3-millimeter spheres. Gastroenterology (1988) 1.23
Absorption potential: estimating the fraction absorbed for orally administered compounds. J Pharm Sci (1985) 1.21
The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J Pharmacokinet Biopharm (1987) 1.20
Moisture sorption kinetics for water-soluble substances. I: Theoretical considerations of heat transport control. J Pharm Sci (1983) 1.19
Plasma levels and pharmacological effects of metoprolol administered as controlled release (Durules) and ordinary tablets in healthy volunteers. Int J Clin Pharmacol Ther Toxicol (1980) 1.17
The effect of pretreatment with cimetidine on the bioavailability and disposition of atenolol and metoprolol. Br J Clin Pharmacol (1982) 1.17
Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev (1996) 1.17
Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics (1992) 1.16
Prediction of physical aging in controlled-release coatings: the application of the relaxation coupling model to glassy cellulose acetate. Pharm Res (1991) 1.14
Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clin Pharmacokinet (1980) 1.13
Influence of physical aging on mechanical properties of polymer free films: the prediction of long-term aging effects on the water permeability and dissolution rate of polymer film-coated tablets. Pharm Res (1991) 1.13
Effects of grapefruit juice ingestion--pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol (1997) 1.12
Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance. Eur J Clin Pharmacol (1992) 1.11
Scaleup of immediate release oral solid dosage forms. Pharm Res (1993) 1.10
Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm Res (2000) 1.09
Pharmacokinetics of trimethoprim and sulfamethoxazole in normal subjects and in patients with renal failure. J Infect Dis (1973) 1.08
Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm Res (1998) 1.07
Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol). J Pharm Sci (2006) 1.07
Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev (2007) 1.06
HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. J Pharm Sci (1996) 1.05
Novel approach to the analysis of in vitro-in vivo relationships. J Pharm Sci (1996) 1.03
Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos (2003) 1.03
Protein denaturation during freezing and thawing in phosphate buffer systems: monomeric and tetrameric beta-galactosidase. Arch Biochem Biophys (2000) 1.02
Biology of membrane transport proteins. Pharm Res (1995) 1.02
The interaction effect of grapefruit juice is maximal after the first glass. Eur J Clin Pharmacol (1998) 1.02
Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm Res (1993) 1.02
Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy. Clin Pharmacol Ther (2011) 1.00
Setting bioequivalence requirements for drug development based on preclinical data: optimizing oral drug delivery systems. J Control Release (1999) 0.98
In vitro and in vivo assessment of adenovirus 41 as a vector for gene delivery to the intestine. Gene Ther (1998) 0.98
A peptide prodrug approach for improving bisphosphonate oral absorption. J Med Chem (2000) 0.98
Metoprolol excretion into breast milk. Br J Clin Pharmacol (1980) 0.98
Role of integrin expression in adenovirus-mediated gene delivery to the intestinal epithelium. Hum Gene Ther (1998) 0.98
Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm Res (1991) 0.98
Solubility of nonelectrolytes in polar solvents II: solubility of aliphatic alcohols in water. J Pharm Sci (1974) 0.97
Absorption of alprenolol in man from tablets with different rates of release. Acta Pharm Suec (1971) 0.96
Solubility of nonelectrolytes in polar solvents IV: nonpolar drugs in mixed solvents. J Pharm Sci (1976) 0.96
Time-dependent oral absorption models. J Pharmacokinet Pharmacodyn (2001) 0.95
Membrane permeability parameters for some amino acids and beta-lactam antibiotics: application of the boundary layer approach. J Theor Biol (1988) 0.95
Dissolution of ionizable water-insoluble drugs: the combined effect of pH and surfactant. J Pharm Sci (2000) 0.95
Combined pharmacokinetic and pharmacodynamic studies on alprenolol and 4-hydroxy-alprenolol in man. Life Sci (1974) 0.95
Human proton/oligopeptide transporter (POT) genes: identification of putative human genes using bioinformatics. AAPS PharmSci (2000) 0.95
Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharm Res (1990) 0.94
Viscoelastic properties of polyacrylic acid gels in mixed solvents. Pharm Res (1992) 0.94
Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter. J Pharmacol Exp Ther (2001) 0.93
Characterization of the oral absorption of beta-lactam antibiotics. I. Cephalosporins: determination of intrinsic membrane absorption parameters in the rat intestine in situ. Pharm Res (1988) 0.93
P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels. J Pharm Sci (1998) 0.93
Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery. Pharm Res (1992) 0.93
Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects. Dig Dis Sci (1987) 0.93
Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. Eur J Pharm Biopharm (1998) 0.93
Analysis of models for determining intestinal wall permeabilities. J Pharm Sci (1980) 0.92
The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites. Clin Pharmacokinet (1980) 0.92
Scaleup of oral extended-release dosage forms. Pharm Res (1993) 0.92
Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852. J Pharm Sci (1989) 0.92
Passive and carrier-mediated intestinal absorption components of captopril. J Pharm Sci (1988) 0.92
Characterization of the oral absorption of beta-lactam antibiotics. II. Competitive absorption and peptide carrier specificity. J Pharm Sci (1989) 0.92
Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci (1986) 0.92
Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion. Eur J Clin Pharmacol (1999) 0.92
Clinical pharmacokinetics of beta-adrenoreceptors blockers. Drugs (1976) 0.91
Pharmacokinetics of metoprolol and its metabolite alpha-OH-metoprolol in healthy, non-smoking, elderly individuals. Eur J Clin Pharmacol (1983) 0.91
Lack of biological interaction of alprenolol and salicylate in man. Eur J Clin Pharmacol (1973) 0.91
In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci (1999) 0.91
Calculation of the aqueous diffusion layer resistance for absorption in a tube: application to intestinal membrane permeability determination. Pharm Res (1991) 0.91
Pharmacokinetics of probenecid following oral doses to human volunteers. J Pharm Sci (1982) 0.90
Modulated drug release using iontophoresis through heterogeneous cation-exchange membranes. 2. Influence of cation-exchanger content on membrane resistance and characteristic times. J Pharm Sci (1994) 0.90
Pharmacokinetics and metabolism of omeprazole in animals and man--an overview. Scand J Gastroenterol Suppl (1985) 0.90
Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. Pharm Res (1997) 0.90
Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. J Pharm Sci (1999) 0.90
Overexpression of human intestinal oligopeptide transporter in mammalian cells via adenoviral transduction. Pharm Res (1998) 0.90
CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci (1999) 0.90
Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers. Br J Clin Pharmacol (1999) 0.90
Beta cyclodextrins enhance adenoviral-mediated gene delivery to the intestine. Pharm Res (1998) 0.89